Nelson, Delia - Curtin University - School of Biomedical Sciences

研究领域

Understanding how the immune system interacts with progressing solid tumours. Understanding how to use immune-based therapies, gene therapies and/or vascular-targeting therapies to treat solid tumours. Understanding how nutrition, in particular lipids, minerals and metals, impact on healthy and anti-tumour immunity

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Cornwall, S., M. Wikstrom, A. Musk, J. Alvarez, A. Nowak, and D. J. Nelson. 2016.“Human mesothelioma induces defects in dendritic cell numbers and antigen processing function which predict survival outcomes.”OncoImmunology 31 Aug 2015. In press. Jackaman, C., T. Yeoh, M. Acuil, J. Gardner, and D. J. Nelson. 2016.“Murine mesothelioma induces locally-proliferating IL-10⁺TNF-a⁺CD206^-CX3CR1⁺ M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.”OncoImmunology 5 (6): 1-17. Brestovac, B., O. Coghlan, C. Jackaman, D. J. Nelson, and D. E. Townsend. 2015.“Sarcostemma viminale activates macrophages to a pro-inflammatory phenotype.”Comparative Clinical Pathology 24 (4): 817-826. Elahy, M., C. Jackaman, J. C. Mamo, V. Lam, S. S. Dhaliwal, C. Giles, D. J. Nelson, and R. Takechi. 2015.“Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment.”Immunity & Ageing 12: 1-9. Gardner, J., C. D. Mamotte, P. Patel, T. Yeoh, C. Jackaman, and D. J. Nelson. 2015.“Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function.”PLoS One 10 (4): na-na. Jackaman, C., D. E. Dye, and D. J. Nelson. 2014.“IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice.”Age 36: 1315-1328. Jackaman, C., and D. J. Nelson. 2014.“Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?.”Experimental Gerontology 54: 53-57. Gardner, J., C. D. Mamotte, T. McGonigle, D. E. Dye, C. Jackaman, and D. J. Nelson. 2014.“Lipid-laden partially-activated plasmacytoid and CD4-CD8[alpha]+ dendritic cells accumulate in tissues in elderly mice.”Immunity & Ageing 11 (1). Nelson, D. J., S. Fisher, and B. W. Robinson. 2014.“The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment.”Journal of Immunology Research 2014 (789069). Jackaman, C., H. G. Radley-Crabb, Z. Soffe, T. Shavlakadze, M. D. Grounds, and D. J. Nelson. 2013.“Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice.”Aging Cell 12 (3): 345-357. Crowe, A., C. Jackaman, K. M. Beddoes, B. Ricciardo, and D. J. Nelson. 2013.“Rapid Copper Acquisition by Developing Murine Mesothelioma: Decreasing Bioavailable Copper Slows Tumor Growth, Normalizes Vessels and Promotes T Cell Infiltration.”PLoS ONE 8 (8): 1-14. Jackaman, C., D. Majewski, S. A. Fox, A. nowak, and D. J. Nelson. 2012.“Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo.”Cancer Immunology, Immunotherapy 61: 2343-2356. Jackaman, C., and D. J. Nelson. 2012.“Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ - independent resolution of treated-turmors and CD4+ -dependent systemic and memory responses.”Cancer Immunology, Immunotherapy 61: 549-560. Jackaman, C., and D. J. Nelson. 2012.“Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses.”Cancer Immunology, Immunotherapy 61 (4): 549-560. Jackaman, C., S. Lansley, J. Allan, B. W. Robinson, and D. J. Nelson. 2012.“IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.”International Immunology 24 (6): 357-368. Khong, A., D. J. Nelson, A. nowak, R. Lake, and B. W. Robinson. 2012.“The use of agonistic anti-CD40 therapy in treatments for cancer.”International Reviews of Immunology 31: 246-266. Nelson, D. J. 2012.“Turning the tumor microenvironment into a self vaccine site.”OncoImmunology 1 (6): 989-991. Nelson, D. J. 2012.“Turning the tumor microenvironment into a self vaccine site.”OncoImmunology 1 (6): 1-3. Jackaman, C., S. Cornwall, P. T. Graham, and D. J. Nelson. 2011.“CD40-activated B cells contribute to mesothelioma tumor regression.”Immunology and Cell Biology 89 (2): 255-267. Jackaman, C., and D. J. Nelson. 2010.“Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution.”Cancer Gene Therapy 17 (6): 429-440.